

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM

(to be used for all correspondence after initial filing)

Total Number of Pages in This Submission


11

Application Number	10/556,229		
Filing Date	November 9, 2005		
First Named Inventor	Besidski, et al		
Art Unit	Unknown		
Examiner Name	Unknown		
		Attorney Docket Number	101062-1P US

ENCLOSURES (Check all that apply)

<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment/Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input checked="" type="checkbox"/> Information Disclosure Statement <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Reply to Missing Parts/ Incomplete Application <input type="checkbox"/> Reply to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation <input type="checkbox"/> Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s) _____ <input type="checkbox"/> Landscape Table on CD	<input type="checkbox"/> After Allowance Communication to TC <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below): Form PTO/SB/08A and Form PTO/SB/08B 60 References
Remarks		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm Name	AstraZeneca Pharmaceuticals (address associated with Customer No. 22466)		
Signature			
Printed name	Kenneth F. Mitchell		
Date	May 23, 2006	Reg. No.	42,007

CERTIFICATE OF TRANSMISSION/MAILING

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below:

Signature			
Typed or printed name	Marie M. Greloch	Date	May 23, 2006

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Appl. No.: 10/556,229	Confirmation No.: Unknown
Applicant: Besidski, <i>et al.</i>	PCT Appl. No.: PCT/SE2004/000738
National Phase Fld (371): November 9, 2005	PCT Filed: May 13, 2004
Docket No.: 101062-1P US	TC/A.U.: Unknown
Customer No.: 22466	Examiner: Unknown

Mail Stop PCT
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

Applicants submit herewith a list of patents and publications for which there may be a duty to disclose in accordance with 37 C.F.R. § 1.56.

In accordance with 37 C.F.R. §§ 1.97 (g) and (h), the filing of this Information Disclosure Statement shall not be construed as a representation that a search has been made or that the information cited is material to patentability as defined in 37 C.F.R. § 1.56.

In accordance with the U.S. Patent Office's partial waiver of the requirement under 37 C.F.R. 1.98(a)(2)(i), only copies of the foreign patent documents and non-patent publications are enclosed.

This Information Disclosure Statement is being filed before the mailing date of a first office action on the merits and therefore, pursuant to 37 C.F.R. § 1.97(b), no fee is required pursuant to 37 C.F.R. § 1.17(p). However, the Commissioner is hereby authorized to charge any deficiency in the fees or credit any overpayment to Deposit Account No. 260166 referencing Attorney Docket No. 101062-1P US.

Respectfully submitted,



Kenneth F. Mitchell
Reg. No.42,007
302-886-7466

Dated:



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>		Application Number	10/556,229
		Filing Date	November 9, 2005
		First Named Inventor	Yevgeni BESIDSKI
		Art Unit	Not Known
		Examiner Name	Not Known
		Attorney Docket Number	101062-1P US
Sheet	1	of	4

U. S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T ⁸
		Country Code ³ ~Number ⁴ ~Kind Code ⁵ (if known)				
/GS/	A4	WO 03/049702	06-19-2003	Amgen Inc.		
	A5	WO 04/024154 A1	03-25-2004	Glaxo Grp Limited		
	A6	WO 99/00115	01-07-1999	Smithkline Beecham PLC		
	A7	WO 03/014064 A1	02-20-2003	Bayer Aktiengesellschaft		
	A8	WO 02/50031 A1	06-27-2002	Glaxo Grp Limited		
	A9	WO 01/12189 A1	02-22-2001	Pharmacia & UpJohn S.P.A.		

Examiner Signature	/Golam Shameem/	Date Considered	11/20/2007
--------------------	-----------------	-----------------	------------

***EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet

1

8

Complete if Known

Application Number	10/556,229
Filing Date	November 9, 2005
First Named Inventor	Yevgeni BESIDSKI
Art Unit	Not Known
Examiner Name	Not Known
Attorney Docket Number	101062-1P US

U. S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)				
/GS/	A10	WO 94/22859	10-13-1994	Bayer Aktiengesellschaft		
	A11	WO 04/000828 A1	12-31-2003	Biovitrum AB		
	A12	WO 02/100822 A1	12-19-2002	Biovitrum AB		
	A13	WO 01/96336 A2	12-20-2001	Warner-Lambert Co		
↓	A14	WO 01/85722 A1	11-15-2001	Cor Therapeutics, Inc.		
	A15	GB 1,186,504	04-02-1970	Fisons Pest Control Lmtd		

Examiner Signature	/Golam Shameem/	Date Considered	11/20/2007
<p>*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.</p>			

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-776-9199) and select option 2.

U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449/PTO		Complete if Known	
		Application Number	10/556,229
		Filing Date	November 9, 2005
		First Named Inventor	Yevgeni BESIDSKI
		Art Unit	Not Known
		Examiner Name	Not Known
		Attorney Docket Number	101062-1P US
Sheet	3	of	4

FOREIGN PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)			
/GS/	A16	WO 03/068749 A1	08-21-2003	Glaxo Group Limited	
	A17	WO 04/024710	03-25-2004	Glaxo Group Limited	
	A18	WO 03/022809 A2	03-20-2003	SmithKline Beecham PLC	
	A19	WO 03/053945 A2	07-03-2003	SmithKline Beecham PLC	
	A20	WO 02/090326 A1	11-14-2002	SmithKline Beecham PLC	
↓	A21	WO 02/072536 A1	09-19-2002	SmithKline Beecham PLC	

Examiner Signature	/Golam Shameem/	Date Considered	11/20/2007
--------------------	-----------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

Complete if Known

Application Number	10/556,229
Filing Date	November 9, 2005
First Named Inventor	Yevgeni BESIDSKI
Art Unit	Not Known
Examiner Name	Not Known
Attorney Docket Number	101062-1P US

Sheet

4 of 4

U. S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)				
/GS/	A22	EP 1 312 601 A1	05-21-2003	Ono Pharmaceutical Co		
	A23	EP 0 419 210 A1	03-27-1991	Pfizer Inc		
↓	A24	EP 0 149 200	12-20-1984	Dr. Karl Thomae GmbH		

Examiner Signature	/Golam Shameem/	Date Considered	11/20/2007
-----------------------	-----------------	--------------------	------------

***EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO				Complete if Known	
				<i>Application Number</i>	10/556,229
				<i>Filing Date</i>	11/09/2005
				<i>First Named Inventor</i>	Yevgeni Besidski
				<i>Art Unit</i>	Not
				<i>Examiner Name</i>	Not Known
Sheet	1	of	4	Attorney Docket Number	101062-1P US

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		
/GS/	A25	MCDONNELL, et al., "7-Hydroxynaphthalen-1-yl-Urea and -Amide Antagonists of Human Vanilloid Receptor 1"; Bioorganic & Medicinal Chemistry Letters 14 (2004), pgs 531-534		T ²
	A26	MUSSO, et al., "Indanylidenes. 1. Design and Synthesis of . . . and Analgesic Activity"; J. Med. Chem 2003, 46, pgs 399-408		
	A27	YIANGOU, et al., "Capsaicin Receptor VR1 and ATP-Gated ion Channel P2X3, in Human Urinary Bladder"; BJU International (2001), 87, pgs 774-779		
	A28	WALKER, et al., "The VR1 Antagonist Capsazepine . . . Inflammatory and Neuropathic Pain"; J. Pharmacology & Experimental Therapeutics, Vol. 304, No. 1, pgs 56-62		
	A29	RASHID, et al., "Novel Expression of Vanilloid . . . in Neuropathic Pain"; J. Pharmacology & Experimental Therapeutics, vol 304, No. 3, pgs 940-948		
	A30	CATERINA, et al., "The Capsaicin Receptor: A Heat-Activated Ion Channel in the Pain Pathway"; Nature, Vol 389, Oct 23, 1997, pgs 816-824		
	A31	TOMINAGA, et al., "The Cloned Capsaicin Receptor Integrates Multiple Pain-Producing Stimuli"; Neuron, Vol 21, September 1998, pgs 531-543		
	A32	HWANG, et al., "Hot Channels in Airways: Pharmacology of the Vanilloid Receptor"; Respiratory, Curr Opin Pharmacol 2002, June, 2(3) pgs 235-242		
	A33	SZALLASI, et al. "Vanilloid (Capsaicin) Receptors in Health and Disease"; Am J Clin Pathol 2002, 118, pgs 110-121		
↓	A34	T.L. GILCHRIST, "Heterocyclic Chemistry", 2nd Edition, Longman Scientific and Technical (1992), pgs 248-282		

Examiner Signature	/Golam Shameem/	Date Considered	11/20/2007
--------------------	-----------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO				<i>Complete if Known</i>	
				<i>Application Number</i>	10/556,229
				<i>Filing Date</i>	11/09/2005
				<i>First Named Inventor</i>	Yevgeni Besidski
				<i>Art Unit</i>	Not
				<i>Examiner Name</i>	Not Known
Sheet	2	of	4	<i>Attorney Docket Number</i>	101062-1P US

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			T ²
/GS/	A35	B. Bijaya Kumar, V. Malla Reddy, Indian Journal of Chemistry, Vol 24B, Oct 1985, pgs 1098-1101, Table 1, Scheme I			
	A36	Anthony Gallard, et al., Journal of Enzyme Inhibition and Medicinal Chemistry, Vol 18, No. 2. 2003, "New N-Pyridinyl(methyl)-N1-Substituted . . . Systemic anti-Inflammatory Agents", pgs 201-208			
	A37	STN International, Accession No. 200:912544, 24 April 2003, CHS 0297096, "1H-Benzimidazole-1-acetamide, N-[3-(trifluoromethyl)phenyl]-CAS Registry No. 294669-15-1			
	A38	STN International, Accession No. 2000:532079, 23 April 2003, BAS 0238979, "1H-Benzimidazole-1-acetamide, N-(3-chlorophenyl)-CAS Registry No. 116488-26-7			
	A39	STN International, Accession No. 2001:10738, 24 April 2003, NS11937, "1H-Indole-3-butanamide, N-(4-methylphenyl)-CAS Registry No. 313550-48-0			
	A40	STN International, Accession No. 2001:1505160, 29 April 2003, AG-690/40696518, "1H-Benzimidazole-1-acetamide,N-(2,3-dichlorophenyl)-, CAS Registry No. 332384-60-8			
	A41	STN International, Accession No. 2002:2035573, 09 July 2002, ASN 1816063, "1H-Benzimidazole-1-acetamide,N-(3-chloro-4-methylphenyl)" -CAS Registry No. 332908-87-9			
	A42	STN International, Accession No. 2002:2042451, 09 July 2002, ASN 4428244, "1H-Benzimidazole-1-acetamide,N-(5-amino-2-methylphenyl)" - CAS registry No. 436095-70-4			
	A43	STN International, Accession No. 2003:454497, 30 April 2003, ASN 5212034, "1H-Indole-3-acetamide, N-[4-(1-methylethyl)phenyl]" - CAS Registry No. 460336-68-9			
↓	A44	STN International, Accession No. 2003:454500, 30 April 2003, ASN 5212038, 1H-Indole-3-acetamide, N-(3,5-dimethoxyphenyl)" - CAS Registry No. 460336-71-4			

Examiner Signature	/Golam Shameem/	Date Considered	11/20/2007
--------------------	-----------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO				Complete if Known	
				<i>Application Number</i>	10/556,229
				<i>Filing Date</i>	11/09/2005
				<i>First Named Inventor</i>	Yevgeni Besidski
				<i>Art Unit</i>	Not
				<i>Examiner Name</i>	Not Known
Sheet	3	of	4	Attorney Docket Number	101062-1P US

NON PATENT LITERATURE DOCUMENTS						
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.				T ²
/GS/	A45	STN International, Accession No. 2003:1778448, 09 July 2002, ASN 3067491, "1H-Benzimidazole-1-acetamide, N-(2-fluorophenyl)" - CAS Registry No. 483326-88-1				
	A46	STN International, Accession No. 2003:1780032, 09 July 2002, ASN 3110045, "1H-Benzimidazole-1-acetamide, 5,6-dimethyl-N-[2-(trifluoromethyl)phenyl]" - CAS Registry No. 483347-09-7				
	A47	STN International, Accession No. 2003:1780036, 09 July 2002, ASN 3110053, "1H-Benzimidazole-1-acetamide,N-(2,4-dimethoxyphenyl)-5,6-dimethyl" - CAS Registry No. 483347-12-2				
	A48	STN International, Accession No. 2003:1780041, 09 July 2002, ASN 3110088, "1H-Benzimidazole-1-acetamide, "N-[4-(dimethylamino)phenyl]-5,6-dimethyl" - CAS Registry No. 483347-17-7				
	A49	STN International, Accession No. 2003:1783073, 09 July 2002, ASN 3212475, "1H-Benzimidazole-1-acetamide, N-(3-fluorophenyl)" - CAS Registry No. 483978-05-8				
	A50	STN International, Accession No. 2003:2842871, 30 April 2003, BAS 5595011, "1H-Indole-3-acetamide, N-(3-fluoro-4-methylphenyl)" - CAS Registry No. 510764-85-9				
	A51	STN International, Accession No. 2003:3562090, 30 April 2003, ZT-5586656, "1H-Indole-3-propanamide,N-[2-(1-methylethyl)phenyl]" - CAS Registry No. 556791-23-2				
	A52	STN International, Accession No. 2003:3425665, 30 April 2003, ZT-2132403, "1H-Indole-3-propanamide, N-[4-(1,1-dimethylethyl)phenyl]" - CAS Registry No. 562052-38-4				
	A53	STN International, Accession No. 2003:3428083, 30 April 2003, ZT-2150185, "1H-Indole-3-propanamide, N-(2-chloro-4-methylphenyl)" - CAS Registry No. 562794-00-7				
↓	A54	STN International, Accession No. 2002:737351, document no. 138:265138, Olgen, Sureyya, et al., "Synthesis and . . . indole-3-acetamide derivatives", & Archiv der Pharmazie (Weinheim, Germany) (2002), 335(7), 331-338				

Examiner Signature	/Golam Shameem/	Date Considered	11/20/2007
--------------------	-----------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO				<i>Complete if Known</i>	
				<i>Application Number</i>	10/556,229
				<i>Filing Date</i>	11/09/2005
				<i>First Named Inventor</i>	Yevgeni Besidski
				<i>Art Unit</i>	Not
				<i>Examiner Name</i>	Not Known
Sheet	4	of	4	<i>Attorney Docket Number</i>	101062-1P US

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		T ²
/GS/	A55	STN International, Accession No. 2002:695939, document n o. 137:232452, Rotta Research Lab, S.p.A., "Preparation of benzamidines having antiinflammatory & immunosuppressive activity", & WO2002070468,A2,20020912		
	A56	STN International, Accession No. 2000:825244, document no. 134:147129, Jamieson, Craig, et al., "A rapid approach for the optimization of polymer supported reagents in synthesis", & Synlett (2000), (11), 1603-1607		
	A57	STN International, Accession No. 1988:610992, document no. 109:210992, Shah, V.H., et al., "Studies on acetamide derivatives. Part-II. Preparation . . . sulfamethazin-4-yl/acetamides", & Jr of the Indian Chemical Society (1987), 64(11), 678-81		
	A58	STN International, Accession No. 1958:31856, document n o. 52:31856, Cacace, Fulvio, et al., "Benzimidazole-N-acetic . . . growth activity", & Atti accad. nazl. Lincei. Rend., Classe sci. fiz., mat. e nat. (1957), 22, 510-13		
	A59	STN International, Accession No. 1993:102385, document no. 118:102385, Gallant, Michel, et al., "A stereoselective synthesis . . . of rebeccamycin", & Jr of Organic Chemistry (1993), 58(2), 343-9		
	A60	STN International, Accession No. 1998:227318, document no. 128:308402, Sanwa Kagaku Kenkyusho Co., Ltd., "Preparation of . . . as antiarteriosclerotics", & JP, A2, 10095766, 19980414		
	A61	STN International, Accession No. 1995:594439, document no. 123:9266, Interneuron Pharm, Inc., "Substituted tryptamines . . . and related compounds", & US,A,5403851,19950404		
	A62	International Search Report for International Application No.PCT/SE2004/000738		
↓	A63	International-Type Search Report		

Examiner Signature	/Golam Shameem/	Date Considered	11/20/2007
--------------------	-----------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.